Neurocrine Biosciences (NBIX) Net Cash Flow Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 32.03% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 28.99% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 37.89% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -49.94% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 37.74% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -41.05% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -62.71% |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 73.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.05% |
| Dec 31, 2025 | 92.82% |
| Sep 30, 2025 | 16.04% |
| Jun 30, 2025 | 38.42% |
| Mar 31, 2025 | 16.16% |
| Dec 31, 2024 | -80.69% |
| Sep 30, 2024 | 78.37% |
| Jun 30, 2024 | -165.25% |
| Mar 31, 2024 | -4.27% |
| Dec 31, 2023 | 43.53% |
| Sep 30, 2023 | 135.66% |
| Jun 30, 2023 | -37.16% |
| Mar 31, 2023 | -60.44% |
| Dec 31, 2022 | 42.99% |
| Sep 30, 2022 | 24.57% |
| Jun 30, 2022 | -52.80% |
| Mar 31, 2022 | 1.42% |
| Dec 31, 2021 | 36.62% |
| Sep 30, 2021 | -57.96% |
| Jun 30, 2021 | 58.03% |